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INTRODUCTION
Tramadol was introduced into the U.S. market in 1995 as a non-
scheduled drug.1 It was made a schedule IV drug in 2014.2 According 
to the Drug Enforcement Agency (DEA), schedule IV drugs have “low 
potential for abuse and low risk of dependence”.2 There are very few 
studies from the U.S. about tramadol abuse with literature from Egypt 
and its abuse potential being recognized more in the Middle East. This 
case report highlighted the potential of tramadol abuse and its signifi-
cance as a gateway drug to developing opioid use disorder.3-5
We report a patient who was exposed to long-term use of tramadol 
for cervical disc protrusion and later developed opioid use disorder 
(OUD). We suspect exposure to tramadol set the patient on a course to 
seek other opiates, perpetuating opioid abuse. While tramadol (Sched-
ule IV) is believed to have a lower abuse potential compared to other 
opiates (Schedule II), providers should be aware of the abuse potential 
that this drug holds. 
CASE REPORT
A 30-year-old female presented with an 8-year history of OUD 
and a history of degenerative disc disease. At 16 years old, the opioid 
naïve patient had a bulging disc of the cervical spine for which she was 
prescribed 50 mg tramadol four times a day. After completion of treat-
ment with tramadol for a year, the patient did not experience cravings 
or withdrawal symptoms. She subsequently used ibuprofen for mild 
cervical and thoracic back pain. 
At 22 years of age, the patient developed worsening cervical pain and 
was prescribed 50 mg of tramadol, four times a day. After about four 
and half months of this regimen, she reported tolerance and increased 
cravings requiring medication more frequently than prescribed. While 
she remained on this prescribed regimen for two years, she also began 
buying tramadol from the streets. After several months, the patient’s 
increased tolerance to tramadol caused her to seek out oxycodone from 
the streets with variable doses. She was able to stop the use of opiates 
but was unable to quit tramadol abuse. 
While struggling to find sellers, the patient attempted to quit tra-
madol and had unsuccessful efforts in cutting down. While trying to 
taper, she developed withdrawal symptoms including opioid hyperal-
gesia causing full-body pain with worsening of her cervical spine pain, 
nausea, vomiting, diarrhea, restlessness, insomnia, and anxiety. The 
patient attempted to quit without assisted withdrawal five to six times 
and developed unrelenting withdrawal symptoms. She also reported 
significant mood changes and thoughts of suicide, with no plan, during 
these periods of withdrawal. She later started methadone through an 
opioid treatment program for unrelenting withdrawal symptoms and 
relapses on tramadol. She developed excessive sedation, nausea, and 
vomiting due to methadone. As she developed intolerability to medica-
tion, she quit to follow-up with a relapse on tramadol. 
The patient was seen later in an addiction clinic, initiated on 
buprenorphine-naloxone therapy and maintained at eight 2 mg doses 
twice a day with no relapses. At that time, the patient reported no crav-
ings, no withdrawal symptoms, no extraneous opiate use, and appeared 
to be tolerating the treatment well.
DISCUSSION
Tramadol is a centrally acting analgesic that works on mu opioid and 
monoamine receptors.6 The drug is both a weak opioid agonist and a 
weak inhibitor of the reuptake of norepinephrine and serotonin. Tra-
madol is administered as a racemic mixture, where each enantiomer 
has its own active metabolite, (+)-O-desmethyltramadol or (-)-O-des-
methyltramadol thought to be responsible for mu-agonist properties.1 
Tramadol’s antagonistic properties on the 5-HT2C receptor could con-
tribute to the drug’s effects on depressive and obsessive-compulsive 
symptoms in patients with pain.6 The half-life for tramadol is about 
5.5 hours with extensive first-pass metabolism in the liver and primary 
excretion (90%) through the kidneys. The drug can be administered 
intravenously, intramuscularly, or orally. 
The recommended dose for tramadol ranges from 50-100 mg every 
six hours, orally or parenterally, for mild to moderate pain.1 Guidelines 
for tramadol use in pediatric populations vary between countries. In 
the U.S., tramadol is not recommended for those less than 16 years old.6 
Our case report showed a 16-year-old who was first introduced to tram-
adol without any complication. However, no conclusions could be made 
on whether her exposure to tramadol at a young age may have pre-
disposed her to tramadol abuse later. In some populations, it also has 
been used to relieve distress related to depression and anxiety.7 Trama-
dol generally is well tolerated with common adverse effects of nausea, 
vomiting, dizziness, drowsiness, sweating, and dry mouth. Unlike other 
opioids, tramadol reports lower adverse effects on respiratory or car-
diovascular parameters at clinical doses in adults or children.6 With 
these findings, tramadol (schedule IV) has been thought to be a safer 
alternative, regarding abuse and adverse effects, compared to other 
opiates (schedule II).
Tramadol was introduced in the U.S. market in 1995 as a non-
scheduled drug for treatment of moderate to moderately severe pain.1 
The MedWatch program of the Food and Drug Administration (FDA) 
received 766 case reports of tramadol abuse and 482 cases of with-
drawal associated with tramadol since the drug entered the market in 
1995 through 2004.8 However, the FDA had no recommendations to 
change the scheduling of tramadol at this point. Tramadol eventually 
was classified as a schedule IV controlled substance in 2014. Sched-
ule IV drugs, according to the DEA, are drugs with a low potential for 
abuse and low risk of dependence. Tramadol also has been reported to 
have a low potential for abuse or dependence with reports of 0.7 to 1.5 
cases of abuse per 100,000 individuals.6 Anecdotally in clinical practice, 
many physicians believe tramadol to be safer. However, tramadol’s low 
potential for abuse or dependence may be overestimated. Furthermore, 
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by access to more potent opioids.8 
This case revealed an opioid naïve individual who became depen-
dent on tramadol after being prescribed for a medical condition. Her 
long-term exposure to this schedule IV opiate, without careful moni-
toring, eventually brought her to find other opiates with more abuse 
potential. More research should be performed to determine the risks of 
opiate addiction due to tramadol in naïve individuals and whether more 
careful monitoring and control of this substance should be undertaken. 
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